Status:
UNKNOWN
Imaging Control Study, 3D Echo, MR and RHC.
Lead Sponsor:
Regina Steringer-Mascherbauer
Conditions:
Pulmonary Arterial Hypertension WHO Group I
Eligibility:
All Genders
18+ years
Brief Summary
The aim of the study is to intensify the follow up of patients with pulmonary arterial hypertension via modern imaging guided methods in due consideration of the possibilities of three-dimensional ech...
Detailed Description
It is not possible to perform a magnetic resonance imaging in all patients and as a result echocardiography is not only done at screening but also during the follow up. The imaging technologies made a...
Eligibility Criteria
Inclusion
- age \>17
- pulmonary arterial hypertension WHO group I who are going to start a therapy with prostanoid
- written informed consent
- Prostanoid naive
- no change of the pulmonary arterial hypertension therapy within 3 weeks of inclusion into the study
Exclusion
- pregnancy and lactation period
- Women of childbearing potential who do not use an effective and secure method for birth control
- severe chronic kidney insufficiency (glomerular filtration rate \<30), which will remain for more than 3 months
- liver insufficiency Child C
- life expectancy shorter than the course of the study (for example because of a malignant disease)
Key Trial Info
Start Date :
July 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2019
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT02198456
Start Date
July 1 2014
End Date
December 1 2019
Last Update
May 23 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Krankenhaus der Elisabethinen Linz GmbH
Linz, Upper Austria, Austria, 4020